Q-omics provides the consensus-scored ZNF415 profile across patient tissues and cancer cell-line models. ZNF415 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF415 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZNF415 RNA expression shows 18,545 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where ZNF415 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF415 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF415 survival associations across molecular data types. ZNF415 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF415 RNA expression–survival associations across cancer types. High ZNF415 expression shows unfavorable associations in KICH, LUSC and SCLC, but favorable associations in UVM, HNSC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF415 RNA expression.
This table summarizes ZNF415 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF415. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF415 shows lower tumor expression in HNSC, COAD, STAD, THCA, READ and KIRC. The HNSC box plot shows higher ZNF415 RNA expression in normal versus tumor tissue (log2 FC = −0.886, t-test p < 0.001).
This table shows molecular features associated with ZNF415 in patient tissues and cancer cell lines. In patient samples, ZNF415 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF415 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
